Penicillin: Difference between revisions
From IDWiki
No edit summary |
(added dosing) |
||
(3 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
==Background== |
==Background== |
||
− | === |
+ | ===Nomenclature=== |
− | * |
+ | *Broadly speaking, formulations of penicillin G are soluble and used for IV or IM administration, and penicillin V is used for oral administration but does not achieve high levels in the serum |
{| class="wikitable" |
{| class="wikitable" |
||
Line 33: | Line 33: | ||
*Directly inhibits [[Penicillin-binding protein|penicillin-binding proteins]] |
*Directly inhibits [[Penicillin-binding protein|penicillin-binding proteins]] |
||
− | === |
+ | ===Spectrum of Activity=== |
− | * |
+ | *Generally active against Gram-positive cocci, especially [[streptococci]] but some strains of [[Staphylococcus aureus]], most [[clostridia]], [[Neisseria]], and some [[Haemophilus influenzae]] |
− | * |
+ | *Not active against aerobic Gram-negative bacilli |
− | * |
+ | *Penicillin G is generally more active than penicillin V across all bacteria |
− | === |
+ | ===Clinical Breakpoints=== |
{| class="wikitable" |
{| class="wikitable" |
||
! rowspan="2" |Species |
! rowspan="2" |Species |
||
Line 60: | Line 60: | ||
| |
| |
||
|- |
|- |
||
− | |[[Enterococcus |
+ | |[[Enterococcus]] |
|≤8 |
|≤8 |
||
| |
| |
||
Line 84: | Line 84: | ||
| |
| |
||
|- |
|- |
||
− | |[[Staphylococcus |
+ | |[[Staphylococcus]] |
|≤0.12 |
|≤0.12 |
||
| |
| |
||
Line 124: | Line 124: | ||
| |
| |
||
|- |
|- |
||
− | |[[Streptococcus |
+ | |[[Streptococcus]] (β-hemolytic) |
|≤0.12 |
|≤0.12 |
||
| |
| |
||
Line 132: | Line 132: | ||
| |
| |
||
|- |
|- |
||
− | |[[Streptococcus |
+ | |[[Streptococcus]] (viridans group) |
|≤0.12 |
|≤0.12 |
||
|0.25-2 |
|0.25-2 |
||
Line 140: | Line 140: | ||
| |
| |
||
|} |
|} |
||
+ | |||
⚫ | |||
+ | == Dosing == |
||
+ | |||
+ | * Benzylpenicillin (penicillin G) |
||
+ | ** Standard dosing: 3 million units (1.8 g) IV q4h, or 4 million units (2.4 g) IV q6h |
||
+ | ** High dose (for critical illness, IE, and CNS penetration): 4 million units (2.4 g ) IV q4h |
||
+ | |||
+ | === Renal Dosing === |
||
+ | |||
+ | ==== Benzylpenicillin (Penicillin G) ==== |
||
+ | {| class="wikitable" |
||
+ | !GFR (mL/min) |
||
+ | !Standard Dose |
||
+ | !High Dose |
||
+ | |- |
||
+ | |>50 |
||
+ | |3 MU (1.8 g) IV q4h, or 4 MU (2.4 g) IV q6h |
||
+ | |4 MU (2.4 g ) IV q4h |
||
+ | |- |
||
+ | |10-50 |
||
+ | |3 MU (1.8 g) IV q6h |
||
+ | |3 MU (1.8 g) IV q4h |
||
+ | |- |
||
+ | |<10 |
||
+ | |3 MU (1.8 g) IV load, then 2 MU (1.2 g) IV q8h |
||
+ | |4 MU (2.4 g) IV load, then 2 MU (1.2 g ) IV q6h |
||
+ | |- |
||
+ | |CRRT |
||
+ | |2 MU (1.2 g) IV q6h |
||
+ | |3 MU (1.8 g) IV q6h |
||
+ | |} |
||
+ | |||
+ | == Safety == |
||
+ | |||
+ | === Adverse Reactions === |
||
+ | |||
+ | ==== Hypersensitivity Reactions ==== |
||
+ | |||
+ | * Can cause any type of [[hypersensitivity reaction]] (I to IV) |
||
+ | * Type I: [[anaphylaxis]] and [[urticaria]] |
||
+ | * Type II: [[autoimmune hemolytic anemia]] |
||
+ | * Type III: [[serum sickness-like reaction]] |
||
+ | * Type IV: |
||
+ | ** Delayed maculopapular drug rash |
||
+ | *** Usually after 7 to 10 days of starting and up to 1 to 3 days after stopping) |
||
+ | *** Progresses over days, with lesions that are relatively fixed |
||
+ | *** Can worsen over a few days after stopping, then resolves over 1 to 2 weeks |
||
+ | *** Pruritis is variable |
||
+ | *** Most commonly occur in the context of a viral infection |
||
+ | ** [[Contact dermatitis]] |
||
⚫ |
Latest revision as of 14:44, 30 August 2022
Background
Nomenclature
- Broadly speaking, formulations of penicillin G are soluble and used for IV or IM administration, and penicillin V is used for oral administration but does not achieve high levels in the serum
Formulation | Other Names | Comments |
---|---|---|
sodium penicillin G | sodium benzylpenicillin
crystalline penicillin |
soluble, used for IV |
procaine penicillin G | procaine benzylpenicillin
procaine penicilli |
less soluble, used for IM |
benzathine penicillin G | DBED penicillin | less soluble than procaine, used for IM |
penicillin V | phenoxymethylpenicillin | used for PO, but poor absorption |
Mechanism of Action
- Directly inhibits penicillin-binding proteins
Spectrum of Activity
- Generally active against Gram-positive cocci, especially streptococci but some strains of Staphylococcus aureus, most clostridia, Neisseria, and some Haemophilus influenzae
- Not active against aerobic Gram-negative bacilli
- Penicillin G is generally more active than penicillin V across all bacteria
Clinical Breakpoints
Species | Breakpoints (μg/mL) | Breakpoints (mm) | ||||
---|---|---|---|---|---|---|
S | I | R | S | I | R | |
Anaerobes except Bacteroides | ≤0.5 | 1 | ≥2 | |||
Enterococcus | ≤8 | ≥16 | ≥15 | ≤14 | ||
Neisseria gonorrhoeae | ≤0.06 | 0.12-1 | ≥2 | ≥47 | 27-46 | ≤26 |
Neisseria meningitidis | ≤0.06 | 0.12-0.25 | ≥0.5 | |||
Staphylococcus | ≤0.12 | ≥0.25 | ≥29 | ≤28 | ||
Streptococcus pneumoniae | ≥20 | |||||
Streptococcus pneumoniae IV (nonmeningitis) | ≤2 | 4 | ≥8 | |||
Streptococcus pneumoniae IV (meningitis) | ≤0.06 | ≥0.12 | ||||
Streptococcus pneumoniae PO (pen V) | ≤0.06 | 0.12-1 | ≥2 | |||
Streptococcus (β-hemolytic) | ≤0.12 | ≥24 | ||||
Streptococcus (viridans group) | ≤0.12 | 0.25-2 | ≥4 |
Dosing
- Benzylpenicillin (penicillin G)
- Standard dosing: 3 million units (1.8 g) IV q4h, or 4 million units (2.4 g) IV q6h
- High dose (for critical illness, IE, and CNS penetration): 4 million units (2.4 g ) IV q4h
Renal Dosing
Benzylpenicillin (Penicillin G)
GFR (mL/min) | Standard Dose | High Dose |
---|---|---|
>50 | 3 MU (1.8 g) IV q4h, or 4 MU (2.4 g) IV q6h | 4 MU (2.4 g ) IV q4h |
10-50 | 3 MU (1.8 g) IV q6h | 3 MU (1.8 g) IV q4h |
<10 | 3 MU (1.8 g) IV load, then 2 MU (1.2 g) IV q8h | 4 MU (2.4 g) IV load, then 2 MU (1.2 g ) IV q6h |
CRRT | 2 MU (1.2 g) IV q6h | 3 MU (1.8 g) IV q6h |
Safety
Adverse Reactions
Hypersensitivity Reactions
- Can cause any type of hypersensitivity reaction (I to IV)
- Type I: anaphylaxis and urticaria
- Type II: autoimmune hemolytic anemia
- Type III: serum sickness-like reaction
- Type IV:
- Delayed maculopapular drug rash
- Usually after 7 to 10 days of starting and up to 1 to 3 days after stopping)
- Progresses over days, with lesions that are relatively fixed
- Can worsen over a few days after stopping, then resolves over 1 to 2 weeks
- Pruritis is variable
- Most commonly occur in the context of a viral infection
- Contact dermatitis
- Delayed maculopapular drug rash